<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923984</url>
  </required_header>
  <id_info>
    <org_study_id>HS24152(B2020-077)</org_study_id>
    <nct_id>NCT04923984</nct_id>
  </id_info>
  <brief_title>Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)</brief_title>
  <acronym>EMMA-Can</acronym>
  <official_title>Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada -EMMA-Can</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EMMA-Can is a prospective cohort study to assess the safety and effectiveness of&#xD;
      MMA-embolization for the treatment of CSDH.&#xD;
&#xD;
      Hypothesis- EMMA reduces the recurrence rate of SDH with or without concomitant surgical&#xD;
      evacuation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of our study is to conduct a prospective cohort study to assess the safety and&#xD;
      effectiveness of MMA embolization for the treatment of CSDH. All patients with CSDH&#xD;
      presenting to the emergency room or to neurosurgical outpatient clinic will be screened for&#xD;
      potential enrollment. If the subject is willing to participate an informed consent will be&#xD;
      obtained.&#xD;
&#xD;
      All patients presenting to the emergency room or in neurosurgery clinic with CSDH diagnosed&#xD;
      on CT scan will be considered for the study. If the patient needs emergent evacuation for&#xD;
      clinical reasons, patient will be taken for surgical evacuation before consideration of EMMA.&#xD;
      Patients that are more likely to have recurrence after surgical evacuation are those with&#xD;
      recurrent CSDH, on antiplatelet or antithrombotic treatment. The EMMA could be used as&#xD;
      primary treatment or in conjunction with surgery in these patients or in patients who may not&#xD;
      be good surgical candidate.&#xD;
&#xD;
      Follow up - All patients will be followed after discharge from the hospital at 1, 3 and 6&#xD;
      months interval. The follow up at 1 and 3 months will include plain CT head of the patient,&#xD;
      which is standard of care for most patients. The follow up at 6 months will be only clinical&#xD;
      follow up.&#xD;
&#xD;
      Patients will be assessed for recurrence of CSDH on CT scan of head. The size of the CSDH&#xD;
      will be measured and compared to previous scans and peri-procedural morbidity and mortality&#xD;
      related to EMMA will be sought. This will be done at 1 and 3 months post EMMA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subdural Hematoma recurrence at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrence of SDH on CT scan of head within 3 months from EMMA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size</measure>
    <time_frame>1 month and 3 months</time_frame>
    <description>Change in size of the CSDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1month, 3months, 6months</time_frame>
    <description>Peri-procedural morbidity and mortality related to EMMA.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Embolization of Middle Meningeal Artery for Subdural Hematoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with CSDH will undergo embolization of Middle Meningeal artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization of the middle meningeal artery</intervention_name>
    <description>embolization of the middle meningeal artery with an embolic agent.</description>
    <arm_group_label>Embolization of Middle Meningeal Artery for Subdural Hematoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with subdural hematoma coming to the emergency room or to neurosurgical&#xD;
             outpatient clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  When informed consent is not possible&#xD;
&#xD;
          -  Known allergy to liquid embolic agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jai Shankar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jai Shankar, MD</last_name>
    <phone>4313734164</phone>
    <email>shivajai1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Alcock, RN</last_name>
    <phone>2047893669</phone>
    <email>salcock@hsc.mb.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Sciences centre</name>
      <address>
        <city>Winnipeg MB</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jai Shankar, MD FRCPC</last_name>
      <phone>431 373 4164</phone>
      <email>shivajai1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Susan Alcock</last_name>
      <phone>204 789 3996</phone>
      <email>salcock@hsc.mb.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jai Shankar, MD FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Jai Shankar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Embolization</keyword>
  <keyword>Middle Meningeal Artery</keyword>
  <keyword>Chronic Subdural Hematoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

